Erica Lessem

1.5k total citations
15 papers, 227 citations indexed

About

Erica Lessem is a scholar working on Infectious Diseases, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Erica Lessem has authored 15 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 9 papers in Epidemiology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Erica Lessem's work include Tuberculosis Research and Epidemiology (14 papers), Pneumocystis jirovecii pneumonia detection and treatment (6 papers) and Pharmaceutical Economics and Policy (4 papers). Erica Lessem is often cited by papers focused on Tuberculosis Research and Epidemiology (14 papers), Pneumocystis jirovecii pneumonia detection and treatment (6 papers) and Pharmaceutical Economics and Policy (4 papers). Erica Lessem collaborates with scholars based in United States, South Africa and Canada. Erica Lessem's co-authors include Jennifer Furin, Grania Brigden, Mike Frick, Dalene von Delft, Vivian Cox, Phumeza Tisile, Jonathan Stillo, Helen Cox, Lindsay McKenna and Michael Rich and has published in prestigious journals such as PLoS ONE, The Lancet Infectious Diseases and Emerging infectious diseases.

In The Last Decade

Erica Lessem

15 papers receiving 211 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erica Lessem United States	9	180	132	53	23	22	15	227
Lindsay McKenna United States	10	191 1.1×	122 0.9×	83 1.6×	22 1.0×	20 0.9×	25	265
Jonathan Stillo United States	7	204 1.1×	144 1.1×	71 1.3×	20 0.9×	9 0.4×	16	252
David Mametja South Africa	6	216 1.2×	166 1.3×	66 1.2×	31 1.3×	15 0.7×	9	264
Bazarragchaa Tsogt Mongolia	4	202 1.1×	149 1.1×	69 1.3×	13 0.6×	11 0.5×	8	245
Valiantsin Rusovich Denmark	6	274 1.5×	227 1.7×	93 1.8×	14 0.6×	15 0.7×	13	337
Nils E. Billo Switzerland	6	128 0.7×	102 0.8×	66 1.2×	19 0.8×	20 0.9×	8	204
Aditya Chandrasekhar United States	5	213 1.2×	145 1.1×	30 0.6×	24 1.0×	17 0.8×	8	285
Johnny Daniels South Africa	12	307 1.7×	273 2.1×	65 1.2×	28 1.2×	12 0.5×	24	376
Kamal Kishore Chopra India	8	146 0.8×	94 0.7×	43 0.8×	17 0.7×	20 0.9×	24	214
Alexandra B. Souza Brazil	9	169 0.9×	133 1.0×	36 0.7×	13 0.6×	11 0.5×	17	222

Countries citing papers authored by Erica Lessem

Since Specialization

Citations

This map shows the geographic impact of Erica Lessem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica Lessem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica Lessem more than expected).

Fields of papers citing papers by Erica Lessem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica Lessem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica Lessem. The network helps show where Erica Lessem may publish in the future.

Co-authorship network of co-authors of Erica Lessem

This figure shows the co-authorship network connecting the top 25 collaborators of Erica Lessem. A scholar is included among the top collaborators of Erica Lessem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erica Lessem. Erica Lessem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Almeida, Ana, et al.. (2021). Hear us! Accounts of people treated with injectables for drug-resistant TB. Public Health Action. 11(3). 146–154. 6 indexed citations

Gotham, Dzintars, Lindsay McKenna, Mike Frick, & Erica Lessem. (2020). Public investments in the clinical development of bedaquiline. PLoS ONE. 15(9). e0239118–e0239118. 15 indexed citations

Rodriguez, Carly A., Meredith B. Brooks, Lorenzo Guglielmetti, et al.. (2019). Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action. 9(1). 32–41. 7 indexed citations

Cox, Vivian, et al.. (2018). Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 22(4). 407–412. 23 indexed citations

Reuter, Anja, Phumeza Tisile, Dalene von Delft, et al.. (2017). The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?. The International Journal of Tuberculosis and Lung Disease. 21(11). 1114–1126. 50 indexed citations

Lessem, Erica, Vivian Cox, & Jennifer Furin. (2017). Bedaquiline or delamanid for rifampin-resistant tuberculosis?. The Lancet Respiratory Medicine. 5(10). 772–774. 1 indexed citations

Furin, Jennifer, et al.. (2016). Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis. Emerging infectious diseases. 22(3). 32 indexed citations

Frick, Mike, et al.. (2016). Falling Short of the Rights to Health and Scientific Progress: Inadequate TB Drug Research and Access.. PubMed. 18(1). 9–24. 8 indexed citations

Lessem, Erica, Helen Cox, Colleen Daniels, et al.. (2015). Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives. International Journal of Infectious Diseases. 32. 56–60. 27 indexed citations

10.

Clayden, Polly, Simon Collins, Mike Frick, et al.. (2015). HIV, HEPATITIS C VIRUS (HCV), AND TUBERCULOSIS (TB) DRUGS, DIAGNOSTICS, VACCINES, PREVENTIVE TECHNOLOGIES, RESEARCH TOWARD A CURE, AND IMMUNE-BASED AND GENE THERAPIES IN DEVELOPMENT. 1 indexed citations

11.

DeLuca, Andrea N., et al.. (2014). Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations. Public Health Action. 4(4). 238–242. 5 indexed citations

12.

DeLuca, Andrea N., et al.. (2014). The evolving role of advocacy in tuberculosis. The Lancet Respiratory Medicine. 2(4). 258–259. 9 indexed citations

13.

Clayden, Polly, Simon Collins, Colleen Daniels, et al.. (2014). 2014 PIPELINE REPORT HIV, HEPATITIS C VIRUS (HCV), AND TUBERCULOSIS (TB) DRUGS, DIAGNOSTICS, VACCINES, PREVENTIVE TECHNOLOGIES, RESEARCH TOWARD A CURE, AND IMMUNE-BASED AND GENE THERAPIES IN DEVELOPMENT. 1 indexed citations

14.

Furin, Jennifer, Grania Brigden, Erica Lessem, & M. C. Becerra. (2013). Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study [Case study]. The International Journal of Tuberculosis and Lung Disease. 17(9). 1239–1241. 10 indexed citations

15.

Lessem, Erica, et al.. (2013). Engaging communities in tuberculosis research. The Lancet Infectious Diseases. 13(6). 540–545. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact